In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Eccles, Chief Executive Officer at ChargePoint Technology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• The journey from a management buy-out (MBO) to running a £20m,100-person, global business.

Chris has managed the global business expansion of ChargePoint across all functions including offices based in the UK, Europe, America and Far East. His background in manufacturing management and precision engineering was instrumental in determining the strategy to outsource manufacturing through strategic acquisitions and equipment investments, including the investment in cleanroom technology and disposable manufacturing processes in 2019 and the managed recruitment of technical resources.

As CEO of ChargePoint, Chris has developed a strong positive culture within ChargePoint, focussed on honesty, integrity, and quality which is ultimately reflected in customer satisfaction, employee retention. And the recent successful acquisition of ChargePoint by Arcline Investment Management.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com